Aytu Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed an update regarding their beneficial ownership of Aytu BioPharma, Inc. common stock, maintaining their holdings below the 5% threshold.
NASDAQ
Laurence W. Lytton and Lytton-Kambara Foundation updated their passive beneficial ownership in AYTU Biopharma, Inc., reporting stakes of 9.99% and 8.8% respectively.
NASDAQ
AWM Investment Company, Inc. has reported a 5.8% beneficial ownership stake in Aytu BioPharma, Inc. as of December 31, 2025.
NASDAQ
Laurence W. Lytton and the Lytton-Kambara Foundation reported a combined beneficial ownership of 9.99% in AYTU BIOPHARMA, INC common stock.
NASDAQ
Philotimo Fund and related entities report zero beneficial ownership in Aytu BioPharma, Inc. as of September 30, 2025, marking a complete divestment.
NASDAQ
AWM Investment Company, Inc. has reported a 6.9% beneficial ownership stake in Aytu BioPharma, Inc., holding 619,874 shares of common stock.
NASDAQ
Stonepine Capital Management and its affiliates disclosed a continued 9.9% beneficial ownership stake in Aytu BioPharma, Inc., comprising common stock and various warrants.
NASDAQ
Kanen Wealth Management LLC and its affiliated funds have reported a combined passive beneficial ownership of 6.4% in Aytu BioPharma, Inc., as detailed in a recent Schedule 13G filing.
NASDAQ
Philotimo Fund, Philotimo Focused Growth & Income Fund, Kanen Wealth Management LLC, and David L. Kanen have collectively disclosed a passive beneficial ownership of 2.7% in Aytu BioPharma, Inc.
NASDAQ
An investment group comprising Philotimo Fund, LP, Philotimo Focused Growth & Income Fund, Kanen Wealth Management LLC, and David L. Kanen has disclosed a collective beneficial ownership of 10.3% in Aytu BioPharma, Inc. common stock.
NASDAQ
Kanen Wealth Management LLC, along with Philotimo Fund, LP and Philotimo Focused Growth & Income Fund, has disclosed a combined passive beneficial ownership of 6.2% in Aytu BioPharma, Inc. common stock.
NASDAQ
Laurence W. Lytton has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in AYTU Biopharma, Inc. as of June 9, 2025.